Patents by Inventor Jeffrey Lockman

Jeffrey Lockman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of Administering Myosin Inhibitors
    Publication number: 20240115568
    Abstract: Methods of administering a myosin inhibitor to a patient and related methods of risk mitigation including controls on distribution are described herein. Methods disclosed herein provide for safe administration of mavacamten and other myosin inhibitors, and mitigate the risk of heart failure due to systolic dysfunction.
    Type: Application
    Filed: December 20, 2023
    Publication date: April 11, 2024
    Inventors: Vidya V. PERERA, Samira MERALI, Amy SEHNERT, Michael CHEUNG, Dewey SETO, Jeffrey LOCKMAN, Marie-Laure PAPI
  • Methods of Administering Myosin Inhibitors
    Publication number: 20230338378
    Abstract: Methods of administering a myosin inhibitor to a patient and related methods of risk mitigation including controls on distribution are described herein. Methods disclosed herein provide for safe administration of mavacamten and other myosin inhibitors, and mitigate the risk of heart failure due to systolic dysfunction.
    Type: Application
    Filed: April 25, 2023
    Publication date: October 26, 2023
    Inventors: Vidya V. PERERA, Samira MERALI, Amy SEHNERT, Michael CHEUNG, Dewey SETO, Jeffrey LOCKMAN, Marie-Laure PAPI
  • 6-SUBSTITUTED AND 7-SUBSTITUTED MORPHINAN ANALOGS AND THE USE THEREOF
    Publication number: 20200148646
    Abstract: The application is directed to compounds of Formula I or II: and pharmaceutically acceptable salts and solvates thereof, wherein R?, R?, R?? R1, R2, R3, R4, R4a, and R20 are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I or II and the pharmaceutically acceptable salts and solvates thereof to treat disorders responsive to the modulation of one or more opioid receptors. Certain compounds of the invention are especially useful for treating pain.
    Type: Application
    Filed: January 10, 2020
    Publication date: May 14, 2020
    Inventors: Jeffrey Lockman, Laykea Tafesse, Jae Hyun Park, Mark A. Youngman
  • 6-substituted and 7-substituted morphinan analogs and the use thereof
    Patent number: 10550088
    Abstract: The application is directed to compounds of Formula I or II: and pharmaceutically acceptable salts and solvates thereof, wherein R?, R?, R?? R1, R2, R3, R4, R4a, and R20 are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I or II and the pharmaceutically acceptable salts and solvates thereof to treat disorders responsive to the modulation of one or more opioid receptors. Certain compounds of the invention are especially useful for treating pain.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: February 4, 2020
    Assignee: Purdue Pharma L.P.
    Inventors: Jeffrey Lockman, Laykea Tafesse, Jae Hyun Park, Mark A. Youngman
  • Pyrimidine carboxamides as sodium channel blockers
    Patent number: 10196364
    Abstract: The present disclosure provides substituted pyrimidine carboxamides of Formula (I) and the pharmaceutically acceptable salts and solvates thereof wherein A1, X, A2, W1, W2, W3, E, Z, and R4 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: February 5, 2019
    Assignee: Purdue Pharma L.P.
    Inventors: Jeffrey Lockman, Chiyou Ni, Jae Hyun Park, Minnie Park, Bin Shao, Laykea Tafesse, Jiangchao Yao, Mark A. Youngman
  • Benzomorphan analogs and the use thereof
    Patent number: 10138207
    Abstract: The present invention is directed to Benzomorphan Analog compounds of the Formula I?, Formula IA?, Formula IB?, Formula IC?, or Formula ID? as shown below; and related Formula I?, Formula IA?, Formula IB?, Formula IC?, or Formula ID?; Formula I, Formula IA, Formula IB, Formula IC, or Formula ID; wherein R1, R2a, R2b, R3 and R4 are as defined herein. Compounds of the Invention are useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: November 27, 2018
    Assignee: Purdue Pharma, L.P.
    Inventors: Jeffrey Lockman, Laykea Tafesse, Jiangchao Yao, Jianming Yu
  • PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS
    Publication number: 20170210713
    Abstract: The present disclosure provides substituted pyrimidine carboxamides of Formula (I) and the pharmaceutically acceptable salts and solvates thereof wherein A1, X, A2, W1, W2, W3, E, Z, and R4 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.
    Type: Application
    Filed: April 6, 2017
    Publication date: July 27, 2017
    Inventors: Jeffrey Lockman, Chiyou Ni, Jae Hyun Park, Minnie Park, Bin Shao, Laykea Tafesse, Jiangchao Yao, Mark A. Youngman
  • Ring-contracted morphinans and the use thereof
    Patent number: 9656962
    Abstract: The application is directed to compounds of Formula (I) or (IA) and pharmaceutically acceptable salts and solvates thereof, wherein R1 R2, R3 and G are defined as set forth in the specification. The invention is also directed to use of compounds of Formula (I) or (IA), and the pharmaceutically acceptable salts and solvates thereof, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 23, 2017
    Assignee: Purdue Pharma L.P.
    Inventors: Jeffrey Lockman, Laykea Tafesse
  • Pyrimidine carboxamides as sodium channel blockers
    Patent number: 9637458
    Abstract: The present disclosure provides substituted pyrimidine carboxamides of Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein A1, X, A2, W1, W2, W3, E, Z, and R4 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: May 2, 2017
    Inventors: Jeffrey Lockman, Chiyou Ni, Jae Hyun Park, Minnie Park, Bin Shao, Laykea Tafesse, Jiangchao Yao, Mark A. Youngman
  • RING-CONTRACTED MORPHINANS AND THE USE THEREOF
    Publication number: 20160340316
    Abstract: The application is directed to compounds of Formula (I) or (IA) and pharmaceutically acceptable salts and solvates thereof, wherein R1 R2, R3 and G are defined as set forth in the specification. The invention is also directed to use of compounds of Formula (I) or(IA), and the pharmaceutically acceptable salts and solvates thereof, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
    Type: Application
    Filed: December 19, 2014
    Publication date: November 24, 2016
    Inventors: Jeffrey Lockman, Laykea Tafesse
  • 6-SUBSTITUTED AND 7-SUBSTITUTED MORPHINAN ANALOGS AND THE USE THEREOF
    Publication number: 20160318872
    Abstract: The application is directed to compounds of Formula I or II: and pharmaceutically acceptable salts and solvates thereof, wherein R?, R?, R?? R1, R2, R3, R4, R4a, and R20 are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I or II and the pharmaceutically acceptable salts and solvates thereof to treat disorders responsive to the modulation of one or more opioid receptors. Certain compounds of the invention are especially useful for treating pain.
    Type: Application
    Filed: October 10, 2014
    Publication date: November 3, 2016
    Inventors: Jeffrey Lockman, Laykea Tafesse, Jae Hyun Park, Mark A. Youngman
  • Pyridonemorphinan analogs and biological activity on opioid receptors
    Patent number: 9403824
    Abstract: The application is directed to compounds of Formula I-A and pharmaceutically acceptable salts and solvates thereof, wherein , R1a-R3a, R4, Y and Za are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I-A to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: August 2, 2016
    Assignee: Purdue Pharma L.P.
    Inventors: Jeffrey Lockman, Laykea Tafesse, Mark A. Youngman
  • Substituted morphinans and the use thereof
    Patent number: 9388162
    Abstract: The application is directed to compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4a, and R4b are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: July 12, 2016
    Assignee: Purdue Pharma L.P.
    Inventors: Andrew Kassick, Jeffrey Lockman, Laykea Tafesse
  • Propellane-based compounds and the use thereof
    Patent number: 9340542
    Abstract: The application is directed to compounds of Formula I and pharmaceutically acceptable salts and solvates thereof, wherein R1-R5 are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I, and the pharmaceutically acceptable salts and solvates thereof, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: May 17, 2016
    Assignee: Purdue Pharma L.P.
    Inventor: Jeffrey Lockman
  • PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS
    Publication number: 20160009659
    Abstract: The present disclosure provides substituted pyrimidine carboxamides of Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein A1, X, A2, W1, W2, W3, E, Z, and R4 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.
    Type: Application
    Filed: March 3, 2014
    Publication date: January 14, 2016
    Inventors: Jeffrey LOCKMAN, Chiyou NI, Jae Hyun PARK, Minnie PARK, Bin SHAO, Laykea TAFESSE, Jiangchao YAO, Mark A. YOUNGMAN
  • BUPRENORPHINE ANALOGS
    Publication number: 20150203504
    Abstract: The present invention is directed to Buprenorphine Analog compounds of Formula I, II, III, IV or V and including various stereoisomers (such as Formula IA shown below), wherein R1, R3a, R3b, R16, R15, G, Q, X, A and Z are as defined herein. Compounds of the Invention may be useful for preparing medicaments useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors. Compounds of the Invention may be useful for treating Conditions such as pain, constipation, and others modulated by activity of opioid and ORL-1 receptors.
    Type: Application
    Filed: January 20, 2015
    Publication date: July 23, 2015
    Inventors: R. Richard Goehring, Laykea Tafesse, Jeffrey Lockman
  • PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS
    Publication number: 20150203494
    Abstract: The application is directed to compounds of Formula I-A and pharmaceutically acceptable salts and solvates thereof, wherein , R1a-R3a, R4, Y and Za are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I-A to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
    Type: Application
    Filed: January 28, 2015
    Publication date: July 23, 2015
    Inventors: Jeffrey LOCKMAN, Laykea Tafesse, Mark A. Youngman
  • PROPELLANE-BASED COMPOUNDS AND THE USE THEREOF
    Publication number: 20150183787
    Abstract: The application is directed to compounds of Formula I and pharmaceutically acceptable salts and solvates thereof, wherein R1-R5 are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I, and the pharmaceutically acceptable salts and solvates thereof, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
    Type: Application
    Filed: December 23, 2014
    Publication date: July 2, 2015
    Inventor: Jeffrey LOCKMAN
  • Substituted Morphinans and the Use Thereof
    Publication number: 20150175571
    Abstract: The application is directed to compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4a, and R4b are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
    Type: Application
    Filed: December 19, 2014
    Publication date: June 25, 2015
    Inventors: Andrew KASSICK, Jeffrey LOCKMAN, Laykea TAFESSE
  • Benzomorphan analogs and the use thereof
    Patent number: 9056836
    Abstract: The present invention is directed to Benzomorphan Analog compounds of the Formula I-ID as shown below, wherein R1, R2a, R2b, R3 and R4 are as defined herein. Compounds of the Invention are useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: June 16, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Jeffrey Lockman, Jae Hyun Park, Laykea Tafesse, Jiangchao Yao, Jianming Yu